U.S. label record. The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Review source snapshots checked August 18, 2026 · Integrity checked August 19, 2026.
A bounded review of two sponsor-funded randomized trials: STEP 1 for weight change and SELECT for cardiovascular outcomes.↗↗
What the reviewed sources report
In the reviewed trials, semaglutide was associated with greater weight reduction than placebo in adults without diabetes, and fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. The findings apply to those studied populations and trial conditions.↗↗
What remains unresolved?
How do benefits and harms change after discontinuation, across populations excluded from these trials, and over longer follow-up?↗↗
For adults with established cardiovascular disease and obesity or overweight, the label covers cardiovascular-risk reduction with injection or tablets. Both formulations cover weight management in adults with obesity, or overweight with a weight-related condition. Injection additionally covers weight management in children aged twelve years and older with obesity, and noncirrhotic MASH with F2–F3 fibrosis in adults. The MASH indication has accelerated approval requiring confirmation of clinical benefit; it does not apply to the tablets. Label: 1 ↗
Which safety limits matter?
The boxed warning reports thyroid C-cell tumors in rodents, with uncertain human relevance. Contraindications include personal or family medullary thyroid carcinoma, MEN 2 and hypersensitivity. Warnings address pancreatitis, gallbladder disease, hypoglycemia with insulin or insulin secretagogues, kidney injury from volume depletion, severe gastrointestinal reactions, retinopathy complications, increased heart rate and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: a8c57f3e8cf2c89501ac3b6077dd7480fb4bf72bb0b42135078f0d3a1f20f8f8. Extracted XML SHA-256: 2f2c51a1fdf57a3a2459f340abfbe1e0283e5c8849d3a844db8c28ede302f6b3.
On January 13, 2026, FDA requested removal of the suicidal-behavior and ideation warning from Wegovy labeling after its review found no increased risk. This records the agency’s request, not a claim that every label version has changed. FDA PDF pp. 1 ↗
More findings and the sources behind them
Selected FDA safety communications, read alongside the separately preserved product-label account and human evidence review.
What supported that finding
FDA combined 91 placebo-controlled trials involving 107,910 participants and examined a separate Sentinel claims cohort. These are class-wide analyses, not a dedicated trial of this peptide or a finding about every possible adverse effect. FDA PDF pp. 2, 3 ↗
The chemical form matters
FDA distinguishes semaglutide sodium and acetate from the active ingredient in approved drugs; it lacks information establishing the same chemical and pharmacologic properties. Evidence about an approved product should not be transferred automatically to those salts. FDA source ↗
What remains to be checked
Reconcile each current product and formulation label with subsequent safety and indication changes.
Appraise remaining eligible trial reports and follow-up studies; this update does not complete the literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
European medicine records · 5 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: insulin icodec;semaglutide. EMA record ↗
Marketing authorisation: 2025-11-24. EMA metadata last updated 2026-02-12. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
5586 retrieved · 2 included · 0 excluded · 5584 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Semaglutide"[Title/Abstract] OR "Wegovy"[Title/Abstract] OR "Ozempic"[Title/Abstract] OR "Rybelsus"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Showing 25 of 5586 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 37952131 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03574597.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 33567185 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03548935.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42738873 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42737751 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736522 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736040 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736027 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735880 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735804 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735799 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42734721 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42734711 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42733032 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732962 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732434 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732089 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730869 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730175 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730115 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730051 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729958 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729808 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729683 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42728029 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42727920 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
6 retrieved · 6 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 6 of 6 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA NDA209637 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
FDA ANDA220314 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
FDA NDA213182 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
FDA NDA215256 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
FDA NDA218316 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
FDA NDA213051 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
5 retrieved · 5 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 5 of 5 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/005422 — include: EMA feed product Wegovy; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/004174 — include: EMA feed product Ozempic; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/004953 — include: EMA feed product Rybelsus; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/006426 — include: EMA feed product Kayshild; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/006279 — include: EMA feed product Kyinsu; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
78 retrieved · 45 included · 0 excluded · 33 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 25 of 78 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 14075 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - Public assessment report
EMA 29427 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - Summary for the public
EMA 47367 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-201905 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 47769 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Public assessment report
EMA 49769 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-201911 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 50994 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-202005 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 53437 — include: Document linked by EMA product number; content unappraised. Rybelsus-EMEA-H-C-PSUSA-00010671-202005 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 54265 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-004174-X-0021 : EPAR - Assessment report - Variation
EMA 54415 — include: Document linked by EMA product number; content unappraised. Wegovy : EPAR - Public Assessment Report
EMA 58573 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 58575 — include: Document linked by EMA product number; content unappraised. Rybelsus-EMEA-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 58910 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 60713 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-5422-II-0009 : EPAR - Assessment Report - Variation
EMA 61952 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-005422-II-0009 : EPAR - Assessment report - Variation
EMA 64756 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-005422-II-0017 : EPAR - Assessment report - Variation
EMA 47766 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - All Authorised presentations
EMA 47768 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Risk management plan
EMA 13667 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 47939 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 7027 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - All Authorised presentations
EMA 69828 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Medicine overview
EMA 72528 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - Medicine overview
EMA 72529 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - Risk management plan
EMA 72531 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - All authorised presentations
EMA 72532 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - Public assessment report
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
783 retrieved · 0 included · 0 excluded · 783 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Semaglutide" OR "Wegovy" OR "Ozempic" OR "Rybelsus" OR "Kayshild" OR "Kyinsu"
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 783 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT00833716 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06546384 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06500143 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06015893 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06977438 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07169136 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07711548 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07627191 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05616013 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07194317 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06065540 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02863419 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05920889 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07770282 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01272973 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03548935 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05227196 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07064486 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06807970 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03631186 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07478653 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05441267 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05700877 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07720466 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04447859 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Semaglutide?
A bounded review of two sponsor-funded randomized trials: STEP 1 for weight change and SELECT for cardiovascular outcomes.12
Bottom line from this bounded source set
In the reviewed trials, semaglutide was associated with greater weight reduction than placebo in adults without diabetes, and fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. The findings apply to those studied populations and trial conditions.12
Reviewed study record
STEP 1 weight-management trial
Design
A double-blind, randomized, placebo-controlled trial followed participants for 68 weeks alongside a lifestyle intervention.1
Population
The trial enrolled 1,961 adults with obesity, or overweight plus at least one weight-related condition, who did not have diabetes.1
Outcomes reported
Mean body-weight change at 68 weeks was -14.9% in the semaglutide group and -2.4% with placebo. Gastrointestinal events were common, and treatment discontinuation for gastrointestinal events was more frequent with semaglutide.1
Limitations
The sponsor-funded trial combined treatment with lifestyle intervention, excluded people with diabetes, and does not by itself establish outcomes after treatment stops.1
Reviewed study record
SELECT cardiovascular-outcomes trial
Design
A multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial assessed a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.2
Population
The trial enrolled 17,604 adults age 45 or older with established cardiovascular disease and overweight or obesity, but no history of diabetes.2
Outcomes reported
A primary cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group; the reported hazard ratio was 0.80. Permanent discontinuation because of adverse events occurred in 16.6% and 8.2%, respectively.2
Limitations
The sponsor-funded findings apply to people with preexisting cardiovascular disease and without diabetes; they do not answer primary prevention for lower-risk populations.2
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2032183. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2307563. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Semaglutide?
U.S. label record. The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Status at observationCompleted 13Recruiting 8Active, not recruiting 5Enrolling by invitation 1Not yet recruiting 1
A phase value is unavailable here for 72 selected records; this is not counted as “no phase.”
A status value is unavailable here for 70 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
41 of 97 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 36Letter 4Observational Study 3Randomized Controlled Trial 2Research Support, Non-U.S. Gov't 2Case Reports 1Clinical Trial, Phase II 1Editorial 1Multicenter Study 1Review 1
Bibliography fields unavailable here for 56 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
5
FDA Federal Register documents
13
DailyMed SPL versions
19
Canonical profile
Published
Profile structured data
Published
Linked dated records
237
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.
PeptideScanner retained ClinicalTrials.gov record NCT03811561 at 2026-09-09T19:17:17.089Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07662213 at 2026-09-09T19:17:17.121Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 40536021 in Qualitative health research as Journal Article, with publication-date metadata of 2025-06-19 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PeptideScanner retained ClinicalTrials.gov record NCT03811561 at 2026-09-09T19:17:17.089Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07662213 at 2026-09-09T19:17:17.121Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PubMed lists PMID 40536021 in Qualitative health research as Journal Article, with publication-date metadata of 2025-06-19 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42703141 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42703150 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42602345 in Canadian journal of kidney health and disease as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained ClinicalTrials.gov record NCT07087795 at 2026-08-13T16:32:13.881Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PubMed lists PMID 41938304 in AACE endocrinology and diabetes as Journal Article, Review, with publication-date metadata of 2026-01-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42076092 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42076118 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42158165 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42232304 in Frontiers in clinical diabetes and healthcare as Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗